Watch More Highlights
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, examines daratumumab (DARA) plus bortezomib, lenalidomide, and dexamethasone (VRd) vs. VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. DARA plus VRd significantly improved progression-free survival and increased the depth of response (LBA-1).